Platinum-induced ototoxicity and hearing impairment in children and adolescents.

Abstract

Platinum compounds play a crucial role in the treatment of solid tumours in paediatric patients, significantly improving survival rates. However, these treatments can result in hearing loss as a side-effect that can significantly impact the quality of life of young cancer survivors. Whilst the therapeutic benefits of platinum compounds in paediatric oncology are indisputable, addressing the challenge of ototoxicity remains a priority. Early and regular auditory function assessments, with tools such as audiometry, otoacoustic emissions and auditory brainstem response testing, are critical during platinum-based therapy, playing key roles in the early detection of hearing loss. Interdisciplinary collaboration amongst paediatric oncologists, audiologists and otolaryngologists is essential for optimal management and to minimize the long-term consequences of hearing loss. This narrative review concludes that, whilst platinum-based chemotherapeutic agents demonstrate significant therapeutic efficacy in paediatric malignancies, platinum-induced ototoxicity remains a substantial clinical challenge. Continued research into prevention, monitoring and treatment strategies is essential for preserving hearing and improving the overall quality of life for survivors of childhood cancer.